Showing 4711-4720 of 8791 results for "".
- Phase 2b Study: AOBiome Therapeutics' Topical B244 Improves Itch, ADhttps://practicaldermatology.com/news/phase-2b-study-aobiome-therapeutics-topical-b244-improves-itch-ad/2461086/AOBiome Therapeutics’ B244 showed positive results from for both Pruritus and Atopic Dermatitis, according to a Phase 2b trial. AOBiome's B244 platform is a patented, proprietary, topical and intranasal formulation. Once deployed, B244 produces nitric
- LEO Pharma A/S Appoints Brian Hilberdink New President of LEO Pharma Inc. United Stateshttps://practicaldermatology.com/news/leo-pharma-as-appoints-brian-hilberdink-new-president-of-leo-pharma-inc-united-states/2461084/LEO Pharma A/S appointed Brian Hilberdink as the new Executive Vice President and President of LEO Pharma Inc. in the United States, effective March 14, 2022. Brian Hilberdink joins LEO Pharma from Novo Nordisk, Inc., in the U.S. where he served as Senior Vice President of Sales.<
- Study: More Than Half of Postmenopausal Women Experience Female Pattern Hair Losshttps://practicaldermatology.com/news/study-more-than-half-of-postmenopausal-women-experience-female-pattern-hair-loss/2461079/More than half of postmenopausal women experience female pattern hair loss, according to a studypublished online in Menopause. In a new cross-sectional study involving 178 women seen at a menopause clinic, researchers aimed to evaluate the prevalence of female pat
- PCA SKIN Looks to Space for Next Breakthrough in Skin Healthhttps://practicaldermatology.com/news/pca-skin-looks-to-space-for-next-breakthrough-in-skin-health/2461077/PCA SKIN plans to send the first-ever private sector skin health experiment to the International Space Station (ISS). The experiment, sponsored by the ISS National Lab, will explore the effects of microgravity on skin-related biomarkers in an effort to guide future product innovat
- GW Dermatology, La Roche-Posay Establish GW Skin Cancer Research Acceleration Fundhttps://practicaldermatology.com/news/gw-dermatology-la-roche-posay-establish-gw-skin-cancer-research-acceleration-fund/2461074/The Department of Dermatology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS) has partnered with La Roche-Posay to establish the La Roche-Posay Skin Cancer Research Acceleration Fund at GW. The $50,000 gift will be used to support the growth
- ASDS Survey Highlights Teledermatology Boom, Staffing Challenges, and Other Ways COVID-19 Upended Practicehttps://practicaldermatology.com/news/asds-survey-sites-teledermatology-boom-staffing-challenges-and-other-ways-pandemic-upended-practice/2461070/From dramatic upticks in the use of teledermatology to staffing challenges and delays in procedures, the ongoing COVID-19 pandemic continues to affect dermatology practices and patients, according to a
- Study: Nutrafol's Core Products Provide Benefits Across Sexes, Ethnicitieshttps://practicaldermatology.com/news/study-nutrafols-core-products-provide-benefits-across-sexes-ethnicities/2461068/Nutrafol’s core products provide improvement in hair growth, coverage, density, and volume across diverse ethnicities, results of a new study show. The six-month, single blind study was conducted by Dr. Sophia Kogan, Tess Marshall, and Dr. Isabelle Raymond to test the effecti
- Study: Bile Acids May Improve Skin Inflammation in Psoriasishttps://practicaldermatology.com/news/study-bile-acids-may-improve-skin-inflammation-in-psoriasis/2461067/Taking bile acids may help control inflammation caused by psoriasis, a UC Davis Health study has found. The study, published in the Journal of Investigative Dermatolog
- Biofrontera Updates Patient Recruitment for Ameluz-PDT Trialhttps://practicaldermatology.com/news/biofrontera-updates-patient-recruitment-for-ameluz-pdt-trial/2461066/Fully 70 percent of the planned 186 patients have been enrolled in Biofrontera Inc.'s phase III clinical study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz photodynamic therapy (Ameluz-PDT) in combination with the BF-RhodoLED lamp in the U.S, the company repor
- Dupixent Update: Medication Shows Promise in Five Inflammatory Diseaseshttps://practicaldermatology.com/news/dupixent-update-medication-shows-promise-in-five-inflammatory-diseases/2461063/Dupixent (dupilumab) performed well across five diseases with underlying type 2 inflammation. The five diseases include eosinophilic esophagitis, chronic spontaneous urticaria, asthma, chronic rhinosinusitis with nasal polyposis, and atopic dermatitis. Additionally, positive result